210 related articles for article (PubMed ID: 37922356)
1. Mutational processes of tobacco smoking and APOBEC activity generate protein-truncating mutations in cancer genomes.
Adler N; Bahcheli AT; Cheng KCL; Al-Zahrani KN; Slobodyanyuk M; Pellegrina D; Schramek D; Reimand J
Sci Adv; 2023 Nov; 9(44):eadh3083. PubMed ID: 37922356
[TBL] [Abstract][Full Text] [Related]
2. Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis.
Petljak M; Alexandrov LB; Brammeld JS; Price S; Wedge DC; Grossmann S; Dawson KJ; Ju YS; Iorio F; Tubio JMC; Koh CC; Georgakopoulos-Soares I; Rodríguez-Martín B; Otlu B; O'Meara S; Butler AP; Menzies A; Bhosle SG; Raine K; Jones DR; Teague JW; Beal K; Latimer C; O'Neill L; Zamora J; Anderson E; Patel N; Maddison M; Ng BL; Graham J; Garnett MJ; McDermott U; Nik-Zainal S; Campbell PJ; Stratton MR
Cell; 2019 Mar; 176(6):1282-1294.e20. PubMed ID: 30849372
[TBL] [Abstract][Full Text] [Related]
3. Mutational signatures associated with tobacco smoking in human cancer.
Alexandrov LB; Ju YS; Haase K; Van Loo P; Martincorena I; Nik-Zainal S; Totoki Y; Fujimoto A; Nakagawa H; Shibata T; Campbell PJ; Vineis P; Phillips DH; Stratton MR
Science; 2016 Nov; 354(6312):618-622. PubMed ID: 27811275
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of APOBEC3 mutagenesis in human cancer cells.
Petljak M; Dananberg A; Chu K; Bergstrom EN; Striepen J; von Morgen P; Chen Y; Shah H; Sale JE; Alexandrov LB; Stratton MR; Maciejowski J
Nature; 2022 Jul; 607(7920):799-807. PubMed ID: 35859169
[TBL] [Abstract][Full Text] [Related]
5. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
Swanton C; McGranahan N; Starrett GJ; Harris RS
Cancer Discov; 2015 Jul; 5(7):704-12. PubMed ID: 26091828
[TBL] [Abstract][Full Text] [Related]
6. Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer.
Kim YA; Wojtowicz D; Sarto Basso R; Sason I; Robinson W; Hochbaum DS; Leiserson MDM; Sharan R; Vadin F; Przytycka TM
Genome Med; 2020 May; 12(1):52. PubMed ID: 32471470
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential.
Butler K; Banday AR
J Hematol Oncol; 2023 Mar; 16(1):31. PubMed ID: 36978147
[TBL] [Abstract][Full Text] [Related]
8. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
9. Molecular origins of APOBEC-associated mutations in cancer.
Petljak M; Maciejowski J
DNA Repair (Amst); 2020 Oct; 94():102905. PubMed ID: 32818816
[TBL] [Abstract][Full Text] [Related]
10. Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer.
Petljak M; Green AM; Maciejowski J; Weitzman MD
Nat Genet; 2022 Nov; 54(11):1599-1608. PubMed ID: 36280735
[TBL] [Abstract][Full Text] [Related]
11. Family-Wide Comparative Analysis of Cytidine and Methylcytidine Deamination by Eleven Human APOBEC Proteins.
Ito F; Fu Y; Kao SA; Yang H; Chen XS
J Mol Biol; 2017 Jun; 429(12):1787-1799. PubMed ID: 28479091
[TBL] [Abstract][Full Text] [Related]
12. Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions.
Wong JKL; Aichmüller C; Schulze M; Hlevnjak M; Elgaafary S; Lichter P; Zapatka M
Nat Commun; 2022 Jan; 13(1):178. PubMed ID: 35013316
[TBL] [Abstract][Full Text] [Related]
13. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
14. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
Vural S; Simon R; Krushkal J
Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
[TBL] [Abstract][Full Text] [Related]
15. APOBEC and ADAR deaminases may cause many single nucleotide polymorphisms curated in the OMIM database.
Lindley RA; Hall NE
Mutat Res; 2018 Jul; 810():33-38. PubMed ID: 29957488
[TBL] [Abstract][Full Text] [Related]
16. Competition for DNA binding between the genome protector replication protein A and the genome modifying APOBEC3 single-stranded DNA deaminases.
Wong L; Sami A; Chelico L
Nucleic Acids Res; 2022 Nov; 50(21):12039-12057. PubMed ID: 36444883
[TBL] [Abstract][Full Text] [Related]
17. Qualitative and Quantitative Analysis of DNA Cytidine Deaminase Activity.
DeWeerd R; Green AM
Methods Mol Biol; 2022; 2444():161-169. PubMed ID: 35290637
[TBL] [Abstract][Full Text] [Related]
18. Patterns and processes of somatic mutations in nine major cancers.
Jia P; Pao W; Zhao Z
BMC Med Genomics; 2014 Feb; 7():11. PubMed ID: 24552141
[TBL] [Abstract][Full Text] [Related]
19. The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness.
Kim K; Calabrese P; Wang S; Qin C; Rao Y; Feng P; Chen XS
Sci Rep; 2022 Sep; 12(1):14972. PubMed ID: 36100631
[TBL] [Abstract][Full Text] [Related]
20. Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
Faden DL; Thomas S; Cantalupo PG; Agrawal N; Myers J; DeRisi J
Oral Oncol; 2017 Nov; 74():8-14. PubMed ID: 29103756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
